Researchers at Kirin Holdings have reportedly found the Lactococcus lactis strain plasma bacterium and demonstrated its ability to stimulate pDC (plasmacytoid dendritic cells), which spur other immune cells into action.
The result is Immuse, an ingredient designed to stimulate the body’s natural defenses. Immuse is a paraprobiotic immune activator that causes pDC to activate Natural Killer Cells (NK cells), Killer T, Helper T, and B cells, the company says. These cells are then delivered to the blood stream and distributed throughout the body as immune support.
Immuse is supported by 11 human clinical trials, consisting of nine efficacy and two safety studies, which determined the ingredient’s long-term impact and its range of immune support.
The trials validated that the ingredient provides clinically researched immune support, activates the immune system via pDC, proactively supports the immune system and stimulates the body’s natural defenses.1
“We are very excited to bring Immuse to the European market. It is a truly unique strain of Lactococcus lactis which activates a broad range of immune cells in our body through the primary activation of pDC cells. This mechanism of action differentiates Immuse from more conventional lactic acid bacteria or other immune ingredients,” said Oksana Ritchie, Head of Marketing at Kyowa Hakko Europe. “In addition, Immuse is a paraprobiotic, a heat-treated probiotic that is more stable and heat resistant which means no refrigeration is required.”
Research deemed Immuse stable for use in various applications. The ingredient is available in Japan and the US, where it’s sold in gummies, tablets, yogurt, and functional beverages. There is also evidence the ingredient may help with work productivity.
For more information about Immuse, visit www.IMMUSEhealth.com
1. These statements have not been evaluated by the Food and Drug Administration or EFSA. This product is not intended to diagnose, treat, cure, or prevent any disease.
